Assessing the impact of the 2018 Changchun Changsheng vaccine incident on childhood vaccination in China.
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
22 Aug 2023
22 Aug 2023
Historique:
received:
21
11
2022
accepted:
25
07
2023
medline:
23
8
2023
pubmed:
23
8
2023
entrez:
22
8
2023
Statut:
epublish
Résumé
The 2018 Changchun Changsheng vaccine incident is an emergent public health event in China with reports of DTaP vaccines with compromised efficacy. This study aimed to estimate the impact of the vaccine incident on real-world vaccination behaviors in China. A cross-sectional survey was conducted in ten provinces in 2019. Vaccination records were collected from 5294 children aged 6-59 months, with information on 75,579 vaccine doses for seven National Immunization Program (NIP) vaccines and two non-NIP vaccines received from 2014 to 2019. Chi-square test, interrupted time series, and logistic regression were used to evaluate the impacts of vaccine incident on vaccination delay, measured as the proportion of delayed doses out of total doses in schedule. Here we show significant increases in doses delayed ≤ 3 months (19.12% to 22.51%, p = 0.000) and > 3 months (7.17% to 11.82%, p = 0.000) for DTaP vaccine after the incident. By scaling nationally, there will be extra 2.1 million doses delayed ≤ 3 months and 2.8 million doses delayed > 3 months in the year following this incident. More guardians choose expensive private-market substitutes containing DTaP elements over government-funded DTaP vaccines. Controlling for socio-demographic factors, doses scheduled after the incident have higher odds of delays for DTaP vaccine (OR: 3.49, 95% CI: 3.08-3.96) and other NIP vaccines (OR: 2.76, 95% CI: 2.55-2.99), but not for non-NIP vaccines. The observed delays in the incident-involved DTaP vaccine immunization reflect the negative effects of the vaccine incident on vaccination behaviors under the NIP. However, its effects seem minimal for non-NIP vaccines. In the 2018 Changchun Changsheng vaccine incident, the vaccine manufacturer was accused of producing substandard vaccines with compromised efficacy. This study assessed the impacts of the vaccine incident on subsequent vaccination of children in China. We found that vaccinations occurred later than normal for the specific vaccine involved in the incident, but there was no impact on the timing of other childhood vaccines. Children’s guardians also chose different vaccines from that involved in the vaccine incident. Information about how children’s guardians reacted to this incident could be used to improve the information provided in future about childhood vaccination, and be used to decide how vaccination programs could respond following similar incidents.
Sections du résumé
BACKGROUND
BACKGROUND
The 2018 Changchun Changsheng vaccine incident is an emergent public health event in China with reports of DTaP vaccines with compromised efficacy. This study aimed to estimate the impact of the vaccine incident on real-world vaccination behaviors in China.
METHODS
METHODS
A cross-sectional survey was conducted in ten provinces in 2019. Vaccination records were collected from 5294 children aged 6-59 months, with information on 75,579 vaccine doses for seven National Immunization Program (NIP) vaccines and two non-NIP vaccines received from 2014 to 2019. Chi-square test, interrupted time series, and logistic regression were used to evaluate the impacts of vaccine incident on vaccination delay, measured as the proportion of delayed doses out of total doses in schedule.
RESULTS
RESULTS
Here we show significant increases in doses delayed ≤ 3 months (19.12% to 22.51%, p = 0.000) and > 3 months (7.17% to 11.82%, p = 0.000) for DTaP vaccine after the incident. By scaling nationally, there will be extra 2.1 million doses delayed ≤ 3 months and 2.8 million doses delayed > 3 months in the year following this incident. More guardians choose expensive private-market substitutes containing DTaP elements over government-funded DTaP vaccines. Controlling for socio-demographic factors, doses scheduled after the incident have higher odds of delays for DTaP vaccine (OR: 3.49, 95% CI: 3.08-3.96) and other NIP vaccines (OR: 2.76, 95% CI: 2.55-2.99), but not for non-NIP vaccines.
CONCLUSIONS
CONCLUSIONS
The observed delays in the incident-involved DTaP vaccine immunization reflect the negative effects of the vaccine incident on vaccination behaviors under the NIP. However, its effects seem minimal for non-NIP vaccines.
In the 2018 Changchun Changsheng vaccine incident, the vaccine manufacturer was accused of producing substandard vaccines with compromised efficacy. This study assessed the impacts of the vaccine incident on subsequent vaccination of children in China. We found that vaccinations occurred later than normal for the specific vaccine involved in the incident, but there was no impact on the timing of other childhood vaccines. Children’s guardians also chose different vaccines from that involved in the vaccine incident. Information about how children’s guardians reacted to this incident could be used to improve the information provided in future about childhood vaccination, and be used to decide how vaccination programs could respond following similar incidents.
Autres résumés
Type: plain-language-summary
(eng)
In the 2018 Changchun Changsheng vaccine incident, the vaccine manufacturer was accused of producing substandard vaccines with compromised efficacy. This study assessed the impacts of the vaccine incident on subsequent vaccination of children in China. We found that vaccinations occurred later than normal for the specific vaccine involved in the incident, but there was no impact on the timing of other childhood vaccines. Children’s guardians also chose different vaccines from that involved in the vaccine incident. Information about how children’s guardians reacted to this incident could be used to improve the information provided in future about childhood vaccination, and be used to decide how vaccination programs could respond following similar incidents.
Identifiants
pubmed: 37608146
doi: 10.1038/s43856-023-00339-0
pii: 10.1038/s43856-023-00339-0
pmc: PMC10444794
doi:
Types de publication
Journal Article
Langues
eng
Pagination
114Informations de copyright
© 2023. Springer Nature Limited.
Références
Vaccines (Basel). 2021 Dec 10;9(12):
pubmed: 34960208
JAMA. 2005 Mar 9;293(10):1204-11
pubmed: 15755943
Lancet. 2018 Aug 4;392(10145):360
pubmed: 30102159
Vaccine. 2020 Nov 3;38(47):7464-7471
pubmed: 33041097
Vaccine. 2019 Oct 8;37(43):6268-6270
pubmed: 31526621
Commun Med (Lond). 2023 Aug 22;3(1):114
pubmed: 37608146
Expert Rev Vaccines. 2022 Sep;21(9):1343-1353
pubmed: 35924631
Drug Saf. 2004;27(12):831-40
pubmed: 15366972
Lancet. 2021 Aug 7;398(10299):503-521
pubmed: 34273291
Clin Microbiol Infect. 2019 Jul;25(7):872-877
pubmed: 30472425
BMC Public Health. 2019 Nov 27;19(1):1564
pubmed: 31771543
Nature. 2018 Aug;560(7716):14-15
pubmed: 30065333
Glob Public Health. 2013;8(10):1138-50
pubmed: 24294986
Vaccine. 2019 Aug 23;37(36):5270-5275
pubmed: 31345640
Int J Epidemiol. 2016 Apr;45(2):441-9
pubmed: 27174834
Int J Epidemiol. 2017 Feb 1;46(1):348-355
pubmed: 27283160
Pediatrics. 2016 Sep;138(3):
pubmed: 27573088
Vaccine. 2019 Jun 6;37(26):3419-3425
pubmed: 31097351
Prev Med. 2021 Apr;145:106423
pubmed: 33440190
Vaccine. 2020 Oct 7;38(43):6751-6756
pubmed: 32891473
J Med Internet Res. 2021 Jun 11;23(6):e27632
pubmed: 34061757
JMIR Public Health Surveill. 2023 Jan 11;9:e40201
pubmed: 36469911
Vaccine. 2014 Apr 17;32(19):2150-9
pubmed: 24598724
Vaccines (Basel). 2020 Jul 22;8(3):
pubmed: 32707831
Vaccine. 2020 Jul 22;38(34):5541-5547
pubmed: 32620373
Vaccine. 2020 Oct 14;38(44):6882-6888
pubmed: 32912643
Lancet. 2015 Jun 27;385(9987):2571
pubmed: 26122153
Trop Med Int Health. 2007 Oct;12(10):1137-8
pubmed: 17956494